In This Section

Continuing Medical Education

Accreditation Statement

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement

AACR has designated this internet live activity for a maximum of 5.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit

Physicians and other health care professionals seeking 5.5 AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Tuesday, December 7, 2021. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Request for Credit Survey

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Printable List of CME-Designated Sessions

Statement of Educational Need, Target Audience, and Learning Objectives

Primary and secondary CNS cancers remain two of the most complicated areas of oncology and need to be better characterized in order for clinicians to be able to properly diagnose and treat patients. Barriers to success include toxicity from treatments, treatments that do not effectively reach the target, an incomplete understanding of the myriad of genetic and epigenetic factors that contribute to brain cancer, and lack of data concerning racial disparities in brain cancer outcomes.

World-recognized researchers in the fields of genetics, neuro-oncology, and neuro-immunology will update physicians about chromatin architecture in brain cancer, epigenetics and epitranscriptomics, and novel therapeutics, while industry professionals will caucus to discuss better drug design for overcoming the blood-brain barrier, and physician scientists will discuss the challenges presented by current treatments. An overarching theme will also highlight the importance of addressing health disparities in order to improve precision medicine.

In order for physicians to improve outcomes of primary and metastatic CNS tumors, they should ideally understand the disease from multiple perspectives, microscopically and macroscopically. This conference will bring together the physicians who are treating the patients for primary disease, adverse reactions to treatment, and resistance to treatment with the scientists who are studying the mechanisms at the transcriptional and epigenetic levels, understanding the contribution of the tumor microenvironment, using models, and recognizing the limitations of current models. Clinicians should come away with a better understanding of CNS tumor biology.

After participating in this CME activity, physicians should be able to:

  1. Analyze chromatin architecture in brain cancer.
  2. Explain how epigenetic and epitranscriptomic modifications contribute to development of brain tumors.
  3. Detect controversies in clinical care of brain cancer.
  4. Evaluate novel drug design for better CNS penetration.
  5. Explain the role of metabolism in the CNS tumor microenvironment.
  6. Integrate novel viral therapeutics for personalizing brain cancer care.
  7. Articulate and implement a better understanding of the need for diversity in clinical trials and cancer models.

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the website of this conference.

Planner and Speaker Financial Disclosure Index

Acknowledgment of Financial or Other Support

The AACR gratefully acknowledges the following commercial supporters:

Professional Education Grants

Servier Pharmaceuticals

Questions about CME?

AACR Virtual Special Conference: Brain Cancer FAQ’s

Please contact the Office of CME at (215) 440-9300 or [email protected].